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Thema Consulting Pty Ltd., Pyrmont, New South Wales, AustraliaA B S T R A C TBackground: Incobotulinumtoxin-A (Xeomins, Merz Pharmaceuti-
cals, Sydney, New South Wales) is a formulation of botulinum neuro-
toxin type A that is free of complexing proteins. Objective: To assess
the cost-effectiveness of incobotulinumtoxin-A administered with
ﬂexible treatment intervals compared to onabotulinumtoxin-A
(Botoxs, Sydney, New South Wales) in blepharospasm and cervical
dystonia from the perspective of Australian health care providers.
Methods: A Markov state transition model was developed to perform a
cost-utility analysis to compare the cost and health beneﬁts of
incobotulinumtoxin-A to that of onabotulinumtoxin-A. The cost-utility
analysis compared incobotulinumtoxin-A treatment, given at minimum
intervals of 6 weeks and maximum intervals of 20 weeks, with
onabotulinumtoxin-A treatment, given at minimum intervals of 12
weeks andmaximum intervals of 20 weeks. The Markov model consisted
of three health states and followed patients in weekly cycles for 5 years.
Only direct health care costs associated with the acquisition and
administration of type A botulinum neurotoxins were included. Utility
values were derived from a prospective, open-labeled cohort study. The
primary outcomemeasure was the incremental cost per quality-adjustedee front matter Copyright & 2016, International S
r Inc. This is an open access article under the CC
ons.org/licenses/by-nc-nd/4.0/).
1016/j.jval.2015.11.009
ri@thema.net.
ndence to: Carmel Guarnieri, Thema Consulting Ptylife-year. Univariate and probabilistic sensitivity analyses were con-
ducted. Results: Incobotulinumtoxin-A was cost-effective compared to
onabotulinumtoxin-A in both blepharospasm and cervical dystonia, with
an incremental cost/quality-adjusted life-year gained of A$ 25,588 and A$
23,794, respectively. Conclusions: Incobotulinumtoxin-A administered at
ﬂexible treatment intervals determined by the needs of the patient was
found to be a cost-effective treatment option when compared to the
administration of onabotulinumtoxin-A in the Australian health care
system. The option to administer incobotulinumtoxin-A according to the
needs of the patient resulted in patients experiencing symptoms for a
fewer number of weeks compared to onabotulinumtoxin-A given at
minimum 12-week intervals.
Keywords: blepharospasm, cervical dystonia, cost-effectiveness,
incobotulinumtoxin-A.
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Blepharospasm (BLEPH) is a focal dystonia that is characterized
by excessive tone in the orbicularis oculi muscle. It causes a
sporadic or permanent involuntary closure of the eye, which
causes a physical deformity and, with exacerbation of the
symptoms, may even lead to visual impairment (functional
blindness). BLEPH can cause severe disability to patients in
leading their everyday lives. For example, patients are either
completely unable to read, watch television, or perform any
housework or can only do so with considerable difﬁculty. Most
of the times, they are unable to leave the house without a
caregiver. BLEPH is usually bilateral but may be more pronounced
on one side than on the other.
Cervical dystonia (CD), also known as spasmodic torticollis,
covers a spectrum of involuntary movements with abnormal
posture of the head and shoulder/neck region. Patients suffergreatly from CD, which can sometimes make everyday
tasks, such as working, cleaning, and eating, impossible to
accomplish.
In Australia, the estimated prevalence of BLEPH and CD is
0.0007% and 0.015%, respectively [1,2]. On the basis of the 2012
population estimates from the Australian Bureau of Statistics [3],
this equates to 1568 patients for BLEPH and 3360 patients for CD.
Medical Beneﬁts Schedule (MBS) [4] and Pharmaceutical Beneﬁts
Schedule (PBS) [5] data report that the Commonwealth spent in
excess of A$ 11 million on treatment with onabotulinumtoxin-A
for these indications in 2013 and 2014.
In Australia, incobotulinumtoxin-A (Xeomins, Merz Pharma-
ceuticals, Sydney, New South Wales) is licensed for the sympto-
matic management of BLEPH and CD in adults, with the inclusion
of ﬂexible treatment intervals (at minimum intervals of 6 weeks
and maximum intervals of 20 weeks) to be determined on the
actual clinical needs of the individual patient.ociety for Pharmacoeconomics and Outcomes Research (ISPOR).
BY-NC-ND license
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weight complex that, in addition to the neurotoxin (150 kD),
contains bacterial nontoxic proteins, such as hemagglutinins and
nonhemagglutinins (i.e., proteins without any therapeutic effect).
In contrast to conventional preparations of BoNT type A (BoNT/A)
such as onabotulinumtoxin-A (Botoxs, Sydney, New South Wales)
and abobotulinumtoxin-A (Dysports, Ispen Biopharmaceuticals,
Melbourne, Victoria), incobotulinumtoxin-A contains pure (150 kD)
neurotoxin, and because it is free from complexing proteins, it has
a low foreign protein content, thereby having a lower immuno-
genic potential than do other available preparations of BoNT/A,
which is a clinical advantage. Such bacterial proteins potentially
play a role as a promoter of an immune reaction, resulting in a loss
of effect and reduction in duration of activity [6].
Furthermore, the additional clostridial proteins found in
conventional BoNT/A formulations are likely to be a risk factor
for the formation of neutralizing antibodies [7], which can
potentially lead to failure of the treatment. A study that analyzed
serum samples of 503 secondary nonresponder patients treated
with onabotulinumtoxin-A, abobotulinumtoxin-A, or both found
that neutralizing antibodies were detected in 44.5% of the
samples tested [8]. This means that repeated application of
incobotulinumtoxin-A, even in high doses, does not induce the
formation of neutralizing antibodies because of the low content
of protein. Therefore, treatment with incobotulinumtoxin-A is
able to provide results similar to those achievable with conven-
tional preparations of BoNT/A without the risk of antibody
formation, providing long-lasting effects [6].
In addition, conventional BoNT/A preparations, such as
onabotulinumtoxin-A and abobotulinumtoxin-A, require refrig-
eration (21–81C) during transport and storage. A deviation from
these requirements can cause breaks in the cold chain. Advan-
tageously, safety issues or decrease in efﬁcacy due to a break in
the cold chain is not a problem with incobotulinumtoxin-A
because vials can be stored at room temperature (up to 251C)
for up to 4 years.
Finally, conventional forms of BoNT/A require a minimum 12-
week interval before re-treatment compared to incobotulinum-
toxin-A, which allows ﬂexible treatment intervals (at minimum
intervals of 6 weeks and maximum intervals of 20 weeks).
Therefore, incobotulinumtoxin-A can be administered in shorter
intervals according to the needs of the patient compared to
onabotulinumtoxin-A. A cross-sectional survey on satisfaction
with treatment with BoNT/A in patients with CD showed that
approximately two-third of the patients preferred individualized
ﬂexible treatment intervals [9].
The objective of this study was to provide evidence of the
cost-effectiveness of incobotulinumtoxin-A when administered
with ﬂexible dosing intervals according to the needs of the
patient when compared to onabotulinumtoxin-A in patients with
BLEPH and CD from the perspective of Australian health care
providers.Methods
Model Structure
The premise underlying the model structure was that patients
treated with type A botulinum neurotoxins will experience a re-
emergence of symptoms at some point after each injection. The
beneﬁt of ﬂexible dosing with incobotulinumtoxin-A at a minimum
of 6 weeks is that it can be administered earlier than onabotuli-
numtoxin-A, thereby sparing the patient these symptoms.
A Markov state transition model was developed to perform a
cost-utility analysis to compare the cost and health beneﬁts
of incobotulinumtoxin-A ﬂexible dosing given at a minimuminterval of 6 weeks and a maximum interval of 20 weeks, with
those of onabotulinumtoxin-A delivered at a minimum interval
of 12 weeks and a maximum interval of 20 weeks (base case).
The dosage for onabotulinumtoxin-A is consistent with the
Australian Product: for BLEPH, “each treatment lasts approxi-
mately three months, following which the procedure can be
repeated as needed …,” and similarly for CD, “the duration of
therapeutic effect reported in the clinical trials showed … a
typical duration of approximately 12 to 16 weeks, depending on
the patient’s individual disease and response” [10].
The Markov model consisted of three health states, with
patients in the model transiting between these health states in
weekly cycles for a time horizon of 5 years. The three health
states of the Markov model were as follows: 1) patient is receiving
treatment (with either incobotulinumtoxin-A or onabotulinum-
toxin-A); 2) patient’s symptoms are adequately controlled follow-
ing treatment; and 3) patient’s symptoms have re-emerged.
Figure 1 illustrates the transition of patients through the
Markov model. All patients began in the model by receiving the
study treatment. Both treatments were assumed to be effective and
patients therefore moved to the “controlled symptoms” health
state. At some point over the ensuing weeks, the patients’ symp-
toms would re-emerge. The rate at which symptoms re-emerged
was assumed to be equal between the incobotulinumtoxin-A and
the onabotulinumtoxin-A treatment groups because the therapeu-
tic effect was considered comparable between incobotulinumtoxin-
A and onabotulinumtoxin-A [11]. Furthermore, there were no
signiﬁcant differences between treatments with regard to the
median time to waning of treatment effect: 10 weeks for
incobotulinumtoxin-A versus 11 weeks for onabotulinumtoxin-A.
Similarly, the time to onset of treatment effect and the duration of
treatment effect demonstrated no statistically signiﬁcant differ-
ences between the two treatment groups [12,13].
The model then determined whether the patient was eligible
for another treatment on the basis of the time since the patient’s
previous injection. If the patient was eligible for treatment, he or
she would transit back to the original health state, immediately
after which the process began again. If the patient was not eligible
for re-treatment, he or she would reside in the health state in
which symptoms were present until such time as the necessary
treatment interval elapsed. The only difference between the
incobotulinumtoxin-A and onabotulinumtoxin-A treatment arms
of the economic model was the treatment interval.
The primary outcome measure of the model was incre-
mental cost per quality-adjusted life-year (QALY) gained for
incobotulinumtoxin-A compared to that for onabotulinumtoxin-
A. All costs and QALYs were discounted at 5% per annum. The
model also compared incobotulinumtoxin-A ﬂexible dosing with
onabotulinumtoxin-A delivered at ﬁxed 12-week dosing intervals
and with onabotulinumtoxin-A delivered at a minimum of 8-week
intervals. Finally, the model also compared incobotulinumtoxin-A
ﬂexible dosing with incobotulinumtoxin-A delivered at ﬁxed 12-
week dosing intervals. Univariate sensitivity analyses were con-
ducted on the base case by substituting the proportion of patients
in each injection interval and the cost of incobotulinumtoxin-A.
Probabilistic sensitivity analyses (PSA) were conducted on the
base case with distributions assigned to the frequency of repeat
dosing and to utility valuation of the responder and the non-
responder health states. Cost and resource utilization variables
were ﬁxed in the PSA because these variables are direct functions
of the frequency at which treatment is required.
Clinical Data
Results from published open-label extension studies evaluating the
safety and efﬁcacy of repeated injections of incobotulinumtoxin-A
in the treatment of BLEPH [14] and CD [15] were used. In both
Fig. 1 – Structure of the Markov model.
V A L U E I N H E A L T H 1 9 ( 2 0 1 6 ) 1 4 5 – 1 5 2 147studies, re-injections of incobotulinumtoxin-A were possible from
as early as 6 weeks up to the time whenever the patient expressed
the need for a new injection.
In the BLEPH indication, the mean injection interval was 12.6
weeks  4.5 weeks (median 12 weeks). In the CD indication, the
mean injection interval was 14.0 weeks  7.4 weeks (median 13
weeks).
Costs
Only direct health care costs associated with the acquisition and
administration of BoNT/A treatments were included in the
model. All costs were in Australian dollars ($A).
The cost per treatment was determined on the number of 100-
unit (U) vials required per treatment and administration costs.
The number of vials required was determined by mean doses of
incobotulinumtoxin-A and onabotulinumtoxin-A presented in
head-to-head clinical trials [12,13]. Each treatment for BLEPH
(either unilateral or bilateral) required a single 100-U vial per
treatment, whereas each treatment for CD required two 100-U
vials per treatment. These doses were consistent with the
recommended doses in the approved product information for
the respective treatments. The cost per 100-U vial for
incobotulinumtoxin-A and onabotulinumtoxin-A was A$ 375.00
and A$ 415.50, respectively (only 100-U vials were available for
BLEPH and CD in Australia at the time of the analysis).
The cost of administering treatment was the same for
incobotulinumtoxin-A and onabotulinumtoxin-A and was based
on the Australian MBS. These costs were A$ 45.05, A$ 124.85, and
A$ 249.75 for unilateral BLEPH, bilateral BLEPH, and CD, respec-
tively (MBS items 18370, 18372, and 18352). Because of the highly
puriﬁed nature of incobotulinumtoxin-A, the lower immunogenic
potential, and the absence of cold chain storage requirements,
the assumption made was that there were no costs associated
with hospitalizations and adverse events or additional costsassociated with the use of incobotulinumtoxin-A relative to
onabotulinumtoxin-A. Costs associated with the management
of the symptoms of BLEPH or CD were also assumed to be equal
across the treatment arms of the model.
Utility Valuation
Quality-of-life (QOL) and QALY gains for incobotulinumtoxin-A
relative to onabotulinumtoxin-A in the economic model were
driven by a reduction in the time with symptoms spent waiting
for the minimum treatment interval to expire. Therefore, utility
values in the Markov model reﬂected the QOL for patients
experiencing symptoms versus those when the condition was
adequately controlled by type A botulinum neurotoxins.
Utility values in the model were derived from a prospective,
open-label cohort study by Hilker et al. [16]. Fifty patients with
cranial dystonia (including BLEPH) and CD treated long-term with
BoNT/A were enrolled in a prospective, open-label cohort study.
The health-related QOL was assessed using the EuroQol ﬁve-
dimensional questionnaire (EQ-5D). Baseline utility values in the
study by Hilker et al. [16] were used to represent the utility value
for the health state in the economic model in which symptoms
had re-emerged. The utility value at the ﬁrst follow-up visit of 6
weeks in the study by Hilker et al. [16] was used to represent the
utility value of patients who were in the health state post-
injection but before symptoms had re-emerged.
The baseline utility value for those with BLEPH in the model
was 0.59 (standard error [SE] ¼ 0.052), which then increased to
0.66 (SE ¼ 0.056) while symptoms were controlled postinjection.
The corresponding utility values for patients with CD were 0.60
(SE ¼ 0.048) and 0.76 (SE ¼ 0.042). Patients in the health state in
which treatment was being administered were assumed to have
the lower of the two utility values unless the injection was
administered before the re-emergence of symptoms.
All Model Variables Are Presented In Table 1.
Table 1 – Model inputs for the base-case analysis.
Model input BLEPH CD
Proportion of the population requiring repeat injections at each time interval,* % (n/N)
6–r10 wk 23.7 (22/93) 22.5 (43/191)
410–r12 wk 32.3 (30/93) 24.6 (47/191)
412–r14 wk 24.7 (23/93) 19.4 (37/191)
414–20 wk 19.4 (18/93) 33.5 (64/191)
6–r10 wk 23.7 (22/93) 22.5 (43/191)
Utility values applied in the economic evaluation,† utility (SD)
Symptoms (nonresponder) 0.59 (0.26) 0.60 (0.24)
Postinjection (responder) 0.66 (0.28) 0.76 (0.21)
Costs applied in the economic evaluation (A$)
Incobotulinumtoxin-A Onabotulinumtoxin-A Incobotulinumtoxin-A Onabotulinumtoxin-A
Price per 100-U vial‡ 375.00 415.50 375.00 415.50
No. of vials/dose§ 1 1 2 2
Administration cost/dose|| 105.41 249.75
Total cost/treatment 480.41 520.91 999.75 1080.75
BLEPH, blepharospasm; CD, cervical dystonia; MBS, Medical Beneﬁts Schedule; PSA, probabilistic sensitivity analysis; U, unit.
* Reference: Dirichlet distributions generated for PSA: Truong et al. [14] (for BLEPH) and Evidente et al. [15] (for CD).
† Reference: Beta distributions generated for PSA: Hilker et al. [16].
‡ Reference: Pharmaceutical Beneﬁts Schedule [5].
§ Rounded up to the nearest whole vial, assumes wastage.
|| MBS item numbers 18370 (unilateral BLEPH) and 18372 (bilateral BLEPH) for BLEPH (weighted average) and 18352 for CD (item numbers before
April 1, 2015).
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Incobotulinumtoxin-A Flexible Dosing Compared to
Onabotulinumtoxin-A Flexible Dosing
Number of Injections
Over the 5-year time horizon, 23.3 injections of incobotulinumtoxin-
A were required per patient compared to 20.1 injections of
onabotulinumtoxin-A in patients with BLEPH. Similarly in patients
with CD, 22.3 injections of incobotulinumtoxin-A were required
compared to 19.3 injections of onabotulinumtoxin-A over the 5-year
time horizon.
Symptoms
In both BLEPH and CD indications, patients who had
incobotulinumtoxin-A spent fewer weeks experiencing symptoms
over 5 years than did patients who had onabotulinumtoxin-A.
Patients with BLEPH who had incobotulinumtoxin-A experienced
symptoms for 23.3 weeks, whereas patients with BLEPH who
had onabotulinumtoxin-A experienced symptoms for 43.5 weeks
over the 5-year time horizon. Patients with CD who had
incobotulinumtoxin-A experienced symptoms for 22.3 weeks,
whereas patients with CD who had onabotulinumtoxin-A experi-
enced symptoms for 41 weeks over the 5-year time horizon.
Cost-Effectiveness in BLEPH
The use of incobotulinumtoxin-A was cost-effective compared to
that of onabotulinumtoxin-A in patients with BLEPH, with an
incremental cost per QALY gained of A$ 25,588. The QALY gain
for incobotulinumtoxin-A (0.0242) was achieved because its admin-
istration was based on the actual needs of the patients, resulting in
patients experiencing symptoms for fewer weeks (Table 2). That is,
as soon as a patient experienced a re-emergence of symptoms, it
was possible to give a new injection as soon as not only after 6
weeks of the last injection but also later than 12 weeks and up to 20
weeks. If a patient taking onabotulinumtoxin-A experienced a
re-emergence of symptoms before a new injection was permitted(i.e., before 12 weeks), the patient had to bear the symptoms until a
new injection was permitted (at a minimum of 12 weeks). There-
fore, patients on incobotulinumtoxin-A experienced symptoms for
a shorter time than did those on onabotulinumtoxin-A.
Cost-Effectiveness in CD
The use of incobotulinumtoxin-A was cost-effective compared to
that of onabotulinumtoxin-A in patients with CD, with an
incremental cost per QALY gained of A$ 23,794. Patients on
incobotulinumtoxin-A spent less time with symptoms, resulting
in a QALY gain of 0.0511, than did those on onabotulinumtoxin-A
(Table 2).
Univariate Sensitivity Analyses
Table 2 presents the results of univariate sensitivity analyses on
the base case. Exploratory post hoc analyses included all
incobotulinumtoxin-A injections that were administered with
injection intervals of 6 to 20 weeks in the treatment of BLEPH
and CD from two prospective, randomized, double-blind, multi-
center studies [17,18] and their extension phases [14,15]. In both
indications, approximately 45% of the treatments were adminis-
tered with injection intervals of less than 12 weeks and 55%
of the treatments were administered with injection intervals
of 12 weeks or more [19]. When these values were used in the
model, keeping all other variables as per the base case,
incobotulinumtoxin-A continued to be a cost-effective option
compared to onabotulinumtoxin-A for both indications (incremen-
tal cost per QALY gain of A$ 34,529 for BLEPH and A$ 28,237 for CD).
When the price of incobotulinumtoxin-A increased from A$
375 to A$ 415.50, keeping all other variables as per the base case,
the incremental cost per QALY gain of incobotulinumtoxin-A
compared to that of onabotulinumtoxin-A rose to A$ 60,244 in the
BLEPH indication and to A$ 55,232 in the CD indication. The rise
in the incremental cost per QALY was driven by the more
frequent injections of incobotulinumtoxin-A that were adminis-
tered over the 5-year time horizon, because these were admin-
istered as per the needs of the patient. Despite the increased
number of injections, patients administered incobotulinumtoxin-
Table 2 – Results of the cost-effectiveness of incobotulinumtoxin-A ﬂexible dosing (minimum 6 wk) compared to that of onabotulinumtoxin-A ﬂexible
dosing (minimum 12 wk).
Type of analysis BLEPH CD
Base-case analysis Incobotulinumtoxin-
A
Onabotulinumtoxin-
A
Difference Incobotulinumtoxin-
A
Onabotulinumtoxin-
A
Difference
Doses (n) 23.28 22.12 3.16 22.29 19.34 2.95
Symptoms (wk) 23.28 43.52 20.24 22.29 40.97 18.68
Total costs (A$) 9,961 9,341 620 19,839 18,622 1,217
QALYs 2.9023 2.8781 0.0242 3.3138 3.2637 0.0511
Incremental cost/QALY (A$) 25,588 23,794
Univariate sensitivity analysis*
Incremental cost (A$) 1,118 2,016
Incremental QALYs 0.0324 0.0714
Incremental cost/QALY (A$) 34,529 28,237
Univariate sensitivity analysis†
Incremental cost (A$) 1,460 2,824
Incremental QALYs 0.0242 0.0511
Incremental cost/QALY(A$) 60,244 55,232
Probabilistic sensitivity
analysis
Incobotulinumtoxin-A Onabotulinumtoxin-A Difference Incobotulinumtoxin-A Onabotulinumtoxin-A Difference
Total costs (95% CI) (A$) 9,969 (9,108–10,791) 9,343 (8,965–9,705) 626 (1–1,293) 19,846 (18,680–21,601) 18,627 (18,103–19,294) 1,220 (279–2,405)
QALYs (95% CI) 2.9023 (2.9000–2.9047) 2.8780 (2.8644–2.8910) 0.0243 (0.0135–
0.0356)
3.3138 (3.3084–3.3174) 3.2626 (3.2343–3.2835) 0.0512 (0.033–
0.0741)
NMB‡ (95% CI) (A$) 104 (–224 to 403) 316 (–182 to 731)
BLEPH, blepharospasm; CD, cervical dystonia; CI, credible interval; NMB, net monetary beneﬁt; QALY, quality-adjusted life-year; U, unit.
* Proportion of patients in each injection interval [19].
† Price equal (A$ 415.50).
‡ Assuming a cost per QALY value of A$ 30,000.
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Fig. 2 – PSA scatterplot for (A) blepharospasm and (B) cervical dystonia. PSA, probabilistic sensitivity analysis.
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administered onabotulinumtoxin-A injections.Probabilistic Sensitivity Analysis
A PSA was performed using 1000 iterations of the base-case
evaluation. Dirichlet distributions for the proportion of the
population requiring repeat injections at each time interval and
beta distributions for utility values assigned to responders and
nonresponders were generated.The PSA found 23.3 injections (95% credible interval
[CI] from the PSA of 22.1–24.6) of incobotulinumtoxin-A were
needed per patient compared to 20.1 injections (95% CI 19.6–20.6)
of onabotulinumtoxin-A in patients with BLEPH. Similarly,
in patients with CD, 22.3 injections (95% CI 21.3–23.3)
of incobotulinumtoxin-A were required per patient over
5 years compared to 19.3 injections (95% CI 18.9–19.7) of
onabotulinumtoxin-A.
Patients with BLEPH who had incobotulinumtoxin-A experi-
enced symptoms for 23.3 weeks (95% CI 22.1–24.6), whereas
Fig. 3 – Cost-effectiveness acceptability curve (WTP threshold in Australian dollars). BLEPH, blepharospasm; CD, cervical
dystonia; WTP, willingness to pay.
V A L U E I N H E A L T H 1 9 ( 2 0 1 6 ) 1 4 5 – 1 5 2 151patients with BLEPH who had onabotulinumtoxin-A experienced
symptoms for 43.6 weeks (95% CI 37.3–51.2) over 5 years. Patients
with CD who had incobotulinumtoxin-A experienced symptoms
for 22.3 weeks (95% CI 21.3–23.3), whereas patients with CD who
had onabotulinumtoxin-A experienced symptoms for 41.0 weeks
(95% CI 35.8–46.3) over 5 years.
Across the 1000 iterations, there was an incremental cost of A
$ 626 (95% CI A$ 246–A$ 1080) in patients with BLEPH and A$ 1220
(95% CI A$ 585–A$ 1844) in patients with CD. In addition,
incobotulinumtoxin-A was associated with more QALYs than
was onabotulinumtoxin-A in 100% of the simulations in the
BLEPH and CD indications (see Fig. 2A, B), with an incremental
QALY gain of 0.0243 (95% CI 0.0179–0.0319) in the BLEPH indica-
tion and 0.0512 (95% CI 0.0397–0.0630) in the CD indication.
Cost-effectiveness acceptability curves (Fig. 3) illustrate the
probability that the use of incobotulinumtoxin-A will be cost-
effective compared to that of onabotulinumtoxin-A at a
willingness-to-pay threshold of A$ 30,000 per QALY, which wasTable 3 – Results of the cost-effectiveness of incobotulinu
to other scenarios.
Model result BLEPH
Onabotulinumtoxin-A
Incremental cost (A$) 247.48
Incremental QALYs 0.0264
Incremental cost/QALY Incobotulinumtoxin-A
Onabotulinumtoxin-A ﬂexible
Incremental cost (A$) 491.17
Incremental QALYs 0.0045
Incremental cost/QALY Incobotulinumtoxin-A
Incobotulinumtoxin-A
Incremental cost (A$) 546.19
Incremental QALYs 0.0264
Incremental cost/QALY (A$) 20,696
BLEPH, blepharospasm; CD, cervical dystonia; QALY, quality-adjusted lif85.4% in the BLEPH indication and 98.5% in the CD indication. Use
of incobotulinumtoxin-A is almost certainly (100% probability)
cost-effective in both indications at a willingness-to-pay thresh-
old of A$ 50,000 per QALY.
Other scenarios
Cost-effectiveness results of incobotulinumtoxin-A ﬂexible dos-
ing (minimum 6 weeks) compared to other scenarios are sum-
marized in Table 3.
When onabotulinumtoxin-A was given at a ﬁxed 12-week
interval, incobotulinumtoxin-A ﬂexible dosing (minimum 6 weeks)
dominated onabotulinumtoxin-A dosing in patients with BLEPH
and CD. Although there was an increase in the number of
injections given in the incobotulinumtoxin-A dosing in this sce-
nario, because injections were given more frequently, this
improved the QOL more than did the onabotulinumtoxin-A dosing,
because patients experienced less time with symptoms by having
symptoms taken care of sooner with incobotulinumtoxin-A.mtoxin-A ﬂexible dosing (minimum 6 wk) compared
CD
ﬁxed 12-wk dosing
1340.29
0.0582
dominates Incobotulinumtoxin-A dominates
dosing (minimum 8 wk)
919.15
0.0098
dominates Incobotulinumtoxin-A dominates
ﬁxed 12-wk dosing
247.05
0.0582
4243
e-year.
V A L U E I N H E A L T H 1 9 ( 2 0 1 6 ) 1 4 5 – 1 5 2152When the minimum dosing interval for onabotulinumtoxin-A
dosing was reduced from 12 weeks to 8 weeks, incobotu-
linumtoxin-A continued to dominate onabotulinumtoxin-A in
both indications.
Finally, the model also compared incobotulinumtoxin-A ﬂex-
ible dosing (between 6 and 20 weeks) with a scenario in which
incobotulinumtoxin-A was given at ﬁxed doses every 12 weeks. In
this situation, incobotulinumtoxin-A ﬂexible dosing was cost-
effective compared to incobotulinumtoxin-A ﬁxed 12-week dos-
ing, with an incremental cost per QALY gained of A$ 20,696 in
patients with BLEPH and A$ 4,243 in patients with cd.Discussion
The use of incobotulinumtoxin-A provides an alternative treat-
ment option for patients with BLEPH and CD, with ﬂexible dosing
intervals of 6 to 20 weeks, determined on actual clinical needs of
the individual patient. Incobotulinumtoxin-A can be adminis-
tered at shorter intervals compared to other preparations of
BoNT/A, such as onabotulinumtoxin-A, which have a minimum
12-week dosing interval. Patients will usually reach a steady state
at which they would require a reinjection and therefore can
develop their own individual treatment schedule in conjunction
with their neurologist.
The cost-effectiveness model presented demonstrated that
the use of incobotulinumtoxin-A at 6- to 20-week intervals was
cost-effective compared to the use of onabotulinumtoxin-A taken
at 12- to 20-week intervals in patients with BLEPH and CD. The
QALYs gained over the 5-year time horizon were higher for
incobotulinumtoxin-A, because patients had the opportunity to
alleviate their symptoms as soon as 6 weeks after the initial
injection, compared to patients taking onabotulinumtoxin-A,
who had to wait till at least 12 weeks. That is, patients had to
wait for a minimum of 12 weeks to have a re-treatment even if
symptoms re-emerged before 12 weeks.
Because of incobotulinumtoxin-A’s highly puriﬁed nature and
the reduced immunogenic potential as compared to other avail-
able preparations of BoNT, the model assumed that there would
be no difference in costs associated with hospitalizations or
adverse events with the use of incobotulinumtoxin-A relative to
onabotulinumtoxin-A and no costs associated with maintaining
a cold chain during transportation for incobotulinumtoxin-A.
Therefore, this model represented a conservative estimate of
cost-effectiveness for incobotulinumtoxin-A.
Incobotulinumtoxin-A is intended to be an alternative to
other BoNT/A preparations in Australia. Therefore, every MBS
item processed for the administration of incobotulinumtoxin-A
will be offset by an equivalent reduction in the number of items
processed for the administration of other BoNT/A preparations,
such as onabotulinumtoxin-A. Without demanding additional
ﬁnancial resources from the Australian health care system, the
use of incobotulinumtoxin-A has the potential to produce cost
savings for the Australian health care system compared to the
use of onabotulinumtoxin-A.Conclusions
The use of incobotulinumtoxin-A presented to be a more cost-
effective treatment option when compared to the use of
onabotulinumtoxin-A in the Australian health care system for
the treatment of patients with BLEPH and CD. The option toadminister incobotulinumtoxin-A at minimum 6-week ﬂexible
intervals as per the needs of the patient results in patients
experiencing symptoms for less time or overtreatment compared
to patients receiving onabotulinumtoxin-A. This increase in utility
gain from incobotulinumtoxin-A resulted in incobotulinumtoxin-
A being the more favorable treatment option compared to
onabotulinumtoxin-A for patients with BLEPH and CD.
Source of ﬁnancial support: This study was ﬁnancially sup-
ported by Merz Pharmaceuticals.
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